IGoR Frequently Asked Questions (FAQs)
To help provide timely information about all aspects of the program, this page is updated periodically in response to questions from potential performers.
Full information about IGoR and the application process is in the solicitation on SAM.gov. Ask questions via the ARPA-H Solutions site linked below. Please note, you will first need to sign-in or register an account to submit a question.
Program Scope, Technical Content & Milestones
We may consider capital equipment requests provided that the investment enables proposers to adapt existing expertise and capabilities in a fundamentally new direction that supports program goals.
Yes, adding new capabilities in a complementary scientific field to an existing cloud laboratory is within scope for TA4, provided that the expansion is in the direction of greater flexibility in executing a broad range of experiments.
Yes, immune-focused disease models would be considered appropriate for IGoR, if they provide sufficient insight into a complex disease to improve therapy. Additionally, we expect any mechanistic models to fit into a modular, multiscale framework as described. In any case, ARPA-H will not fund the same model development efforts that are already/could be funded by existing ARPA-H, NIH, or other life sciences funding.
Yes, patient-derived samples are allowed, provided that HIPAA requirements are followed.
A pathophysiological process that is common across a range of diseases would be in scope for TA1, and application to therapies for more than one disease would satisfy this metric.
IGoR does not have commercialization requirements for the software generated; however, performers will be expected to participate in the setting of standards through working groups, bake-offs, and requests-for-comment.
One goal of IGoR is to demonstrate the utility of the system on real biological problems. This utility will be assessed by a panel at the end of Phase I. A novel drug candidate would be one potential way to demonstrate insights from the system and overall utility but is not required. Regulatory approval or commercialization of novel therapeutics is out of scope for IGoR.
Eligibility, Teaming, and Team Composition
ARPA-H anticipates awarding approximately three multidisciplinary teams, each addressing all four components.
FFRDCs and U.S. Government entities, including federal Government employees, are not permitted to respond to the ISO as a prime or sub-performer on a proposed performer team.
The IV&V role will not be competed.
Organizations are not limited in the number of proposals that can be submitted.
Solution Summary Submission and Review Questions
Solution Summaries have a limit of five (5) pages.